App-Quantinova.ai

Adenovirus IL-12 and Docetaxel in Combination with Anti-PD1 as an Effective Treatment Strategy for TNBC

Wei Qian - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Sarcoma

Docetaxel

KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Christian Gratzke - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Prostate cancer

Docetaxel

Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)

Evan Yu - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

Kevin Harrington - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Docetaxel

Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma: INTERACTION phase II study.

Stefano Chong Hun Kim - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Docetaxel

Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).

Jing Liu - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastric Cancer

Docetaxel

A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

Ken Kato - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Docetaxel

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).

Eric Van Cutsem - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.

Kuaile Zhao - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.

Koosha Paydary - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

PIONEER: A multicenter, open-label, randomized phase II trial of second-line apatinib plus chemotherapy versus chemotherapy alone in gastric and gastroesophageal junction adenocarcinoma (GA/GEA) refractory to or intolerant of prior anti-PD-1 therapy.

Dandan Yu - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Docetaxel

A prospective, multicenter, dose-escalation, and dose-expansion study evaluating apatinib plus chemotherapy in second-line therapy of patients with postoperatively gastric cancer (ACHIEVE).

Junyi Han - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Docetaxel

INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).

Nick Pavlakis - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A single institution experience.

Winston Wong - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

Docetaxel

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Kiyotaka Yoh - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Genomic characteristics of breast cancer to predict response of neoadjuvant chemotherapy and long-term prognosis.

Ji-Yeon Kim - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Docetaxel

Blood tests to predict one- to two-year survival of patients with difficult cancers.

Robert L. De Jager - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Docetaxel

CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.

Joel W. Neal - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Characteristics and comorbidities of veterans treated with enzalutamide or abiraterone.

Mukti Patel - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Docetaxel

Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).

Steven Attia - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Soft tissue sarcoma

Docetaxel

Filters

2459 Abstracts